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https://doi.org/10.1002/nbm.3901Measurements of hyperpolarized 13C label exchange between injected [1‐13C]pyruvate and the
endogenous tumor lactate pool can give an apparent first‐order rate constant for the exchange.
The determination of the isotope flux, however, requires an estimate of the labeled pyruvate con-
centration in the tumor. This was achieved here by measurement of the tumor uptake of [1‐14C]
pyruvate, which showed that <2% of the injected pyruvate reached the tumor site. Multiplication
of this estimated labeled pyruvate concentration in the tumor with the apparent first‐order rate
constant for hyperpolarized 13C label exchange gave an isotope flux that showed good agreement
with a flux determined directly by the injection of non‐polarized [3‐13C]pyruvate, rapid excision
of the tumor after 30 s and measurement of 13C‐labeled lactate concentrations in tumor extracts.
The distribution of labeled lactate between intra‐ and extracellular compartments and the blood
pool was investigated by imaging, by measurement of the labeled lactate concentration in blood
and tumor, and by examination of the effects of a gadolinium contrast agent and a lactate trans-
port inhibitor on the intensity of the hyperpolarized [1‐13C]lactate signal. These measurements
showed that there was significant export of labeled lactate from the tumor, but that labeled lac-
tate in the blood pool produced by the injection of hyperpolarized [1‐13C]pyruvate showed only
relatively low levels of polarization. This study shows that measurements of hyperpolarized 13C
label exchange between pyruvate and lactate in a murine tumor model can provide an estimate
of the true isotope flux if the concentration of labeled pyruvate that reaches the tumor can be
determined.
KEYWORDS
hyperpolarized 13C, lactate, metabolism, pyruvate, tumor1 | INTRODUCTION
Metabolic imaging has long been used in the clinic, where it has been demonstrated to add value to standard anatomical imaging.1 The leading met-
abolic imaging technique, positron emission tomography (PET), when used with the glucose analog, 18F‐fluorodeoxyglucose (FDG), provides a- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 of 10 SERRAO ET AL.measure of tissue glycolytic activity, which is frequently upregulated in tumors.2 FDG‐PET can be used to detect the presence of cancer, monitor
disease progression and detect tumor responses to treatment.1,3 The introduction of hyperpolarized 13C‐labeled cell substrates has enabled a new
approach to metabolic imaging. Nuclear spin hyperpolarization of 13C‐labeled molecules can increase their sensitivity to detection in the 13C nuclear
magnetic resonance (NMR) experiment by more than 10 000‐fold.4 Intravenous injection of hyperpolarized 13C‐labeled cell substrates and subsequent
13C magnetic resonance spectroscopic imaging (MRSI) enable the real‐time imaging of tissue metabolism in the clinic, in tumors5 and in the heart.6
Hyperpolarized [1‐13C]pyruvate is the best‐established substrate, mainly as a result of its relatively long polarization half‐life (~30 s in vivo), rapid
plasma membrane transport and subsequent metabolism.7,8 Pyruvate is well tolerated at relatively high concentrations and has a history of safe use
in humans as well as in animals.5 Under pathological conditions that lead to upregulated glycolysis, such as in the majority of tumors, pyruvate, which
is the end product of glycolysis, is not oxidized, but is rapidly and reversibly reduced by nicotinamide adenine dinucleotide (NADH) to generate lactate,
in a reaction catalyzed by lactate dehydrogenase (LDH). Similarly to FDG‐PET, MRS(I) measurements of hyperpolarized 13C label exchange between
injected [1‐13C]pyruvate and endogenous lactate have been used in cancer to detect disease and monitor disease progression,9,10 and to assess early
tumor responses to treatment.11,12 The experiment has an advantage over FDG‐PET in that it does not involve the use of ionizing radiation, which
could allow multiple repeat measurements in an individual patient, for example to guide treatment, and it assesses a unique metabolic feature of
tumors, i.e. their preference to reduce pyruvate to lactate rather than oxidize it in the mitochondrial tricarboxylic acid (TCA) cycle. FDG‐PET measures
glucose uptake and subsequent phosphorylation, which can be upregulated in normal tissues, such as the brain, as well as in tumors.
13C labeling of the endogenous lactate pool following the injection of hyperpolarized [1‐13C]pyruvate is often characterized by the [1‐13C]lactate/
[1‐13C]pyruvate signal ratio or by an apparent first‐order exchange rate constant if the metabolite signals are analyzed as a function of time.7,8,11 How-
ever, as the concentrations of labeled pyruvate and lactate cannot be determined from their signal intensities, it is not possible to determine a meta-
bolically relevant flux, for example, in mM/s.13 This is a problem as changes in this apparent first‐order rate constant could be the result of a
metabolically relevant change in isotope flux, resulting, for example, from a change in LDH concentration or a change in the concentration of pyruvate
that actually reaches the exchange site. This is not a significant problem for preclinical studies as, typically, inbred strains of mice are used and, in the
case of tumors, nearly identical tumors are implanted, or autochthonous tumors arise at the same site, and therefore variations in pyruvate delivery are
less likely. However, this is likely to be much more of a problem in the clinic.
Here, we have used measurements with [1‐14C]pyruvate to show that less than 2% of the injected pyruvate reaches the tumor site. Estimates
of this tumor pyruvate concentration, together with the apparent first‐order rate constant describing 13C label exchange between injected
hyperpolarized [1‐13C]pyruvate and the endogenous lactate pool, were used to estimate isotope label flux. This showed good agreement with
the flux estimated directly from measurements of [3‐13C]lactate concentrations in extracts of tumors from animals injected with [3‐13C]pyruvate.
Injection of hyperpolarized [1‐13C]pyruvate into animals treated with a lactate transport inhibitor and injected with a gadolinium chelate, and anal-
ysis of changes in the hyperpolarized [1‐13C]lactate signal intensity, showed that there was significant export of labeled lactate from the tumor cell
in vivo. The contribution of any lactate that is labeled elsewhere in the body and washes into the tissue of interest has previously been assumed to
be negligible as imaging studies with hyperpolarized [1‐13C]pyruvate in this and other tumor models have shown the presence of only low levels of
labeled lactate in the blood pool.11,14,15 Here, we examined this assumption in more detail and showed that there are significant levels of labeled
lactate in the blood at 30 s after injection of labeled pyruvate, determined by measurement of the thermally polarized 13C in tissue extracts.
However, 13C imaging measurements performed with hyperpolarized [1‐13C]pyruvate in this study and previously14 show no evidence for the
appearance of labeled lactate, suggesting that it has only relatively low levels of polarization.2 | METHODS
2.1 | Tumor implantation
All animal experiments were conducted in accordance with project and personal licenses issued under the UK Animals (Scientific Procedures) Act,
1986. Protocols were approved by the Cancer Research UK, Cambridge Institute Animal Welfare and Ethical Review Body.
Tumors were established by subcutaneous inoculation of a suspension of 5 × 106 viable EL4 murine lymphoma cells (in a volume of 100 μL) in the
left flank of C57BL/6 mice (Charles River Ltd., Harlow, Essex, UK) (n = 69) at 6–8 weeks of age, when the animals were ~20 g. Studies were performed
when the tumors had grown to a size of ~2 cm3, which was typically 10 days following implantation. Animals, which were not submitted to any dietary
restriction,16 were anesthetized by either inhalation of 1–2% isoflurane (Isoflo, Abbotts Laboratories Ltd., Maidenhead, Berkshire, UK) in air/O2 (75%/
25%, 2 L/min) or by intraperitoneal administration of 10 mL/kg body weight of a 5: 4: 31 mixture of Hypnorm (VetaPharma, Sherburn‐in‐Elmet, Leeds,
North Yorkshire, UK), Hypnovel (Roche, Welwyn Garden City, Hertfordshire, UK) and saline (n = 5). Body temperature was maintained by blowing
warm air through the magnet bore. The breathing rate (~80 beats/min) and body temperature (37°C) were monitored during the experiments (Biotrig,
Small Animal Instruments, Stony Brook, New York, USA). Agents were injected intravenously via a tail vein catheter.
For some experiments (n = 6), the transport of hyperpolarized [1‐13C]pyruvate and [1‐13C]lactate was inhibited by injecting a monocarboxylate
transporter (MCT) inhibitor, α‐cyano‐4‐hydroxycinnamate (4‐CIN, 150 mg/kg, 0.2 mL intravenously),17 3 min (n = 2) and 30 min (n = 4) prior to the
injection of hyperpolarized [1‐13C]pyruvate (10 mL/kg, 82mM). There was no difference between these two groups of animals in the results
obtained (data not shown).
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Pyruvate was hyperpolarized as described previously.4 Briefly, [1‐13C]pyruvic acid samples (44 mg, 14 mol/L; 91% 13C) containing 15 mmol/L of
trityl radical, tris(8‐carboxy‐2,2,6,6‐tetra‐(hydroxyethyl)‐benzo‐[1,2‐4,5]‐bis‐(1,3)‐dithiole‐4‐yl)‐methyl sodium salt (OX063; GE Healthcare,
Amersham, Buckinghamshire, UK) and 1.5 mmol/L gadolinium chelate (Dotarem, Guerbet Laboratories Ltd, Solihull, West Midlands, UK) were
polarized using a microwave source at 93.982 GHz and 100 mW for 1 h in a 3.35‐T Hypersense (Oxford Biotools, Abingdon, Oxfordshire, UK)
polarizer. The frozen sample was then dissolved at 180°C in 6 mL of buffer containing 40mM N‐2‐hydroxyethylpiperazine‐N′‐2‐ethanesulfonic acid
(HEPES), 94mM NaOH, 30mM NaCl and 50 mg/L ethylenediaminetetraacetic acid (EDTA). Polarization levels ranged from 16% to 25%, measured
using a polarimeter (Oxford Instruments, Abingdon, Oxfordshire, UK).
2.3 | MRS and MRSI
Experiments were performed in a 7.0‐T horizontal bore magnet (Agilent, Palo Alto, CA, USA) using an actively decoupled dual‐tuned 13C/1H volume
transmit coil (Rapid Biomedical, GmbH, Rimpar, Germany; inner diameter, 42 mm) and a 20‐mm‐diameter 13C surface receiver coil (Rapid Biomed-
ical) placed over the tumor. In order to localize the tumor, transverse 1H images were acquired using a spin‐echo pulse sequence [repetition time
(TR), 1.5 s; echo time (TE), 10 ms; field of view, 40 mm × 40 mm; data matrix, 128 × 128 points; slice thickness, 2 mm; 15 slices]. Hyperpolarized [1‐
13C]pyruvate (10 mL/kg, 82mM) was injected intravenously during data acquisition. Single transient spectra from a 6‐mm‐thick tumor slice were
collected using a slice‐selective excitation pulse with a nominal flip angle of 10° (n = 15). One hundred and eighty 13C spectra were acquired with
a TR of 1 s. In some of these experiments (n = 10), a gadolinium chelate [300 μL of 0.05 mmol/mL (~0.75 mmol/kg) Prohance, Bracco, Italy] was
injected as a bolus via a tail vein catheter over a period of 2–3 s, 30–40 s after the start of injection of hyperpolarized [1‐13C]pyruvate, as described
previously.18,19 The data were analyzed in Matlab (The Mathworks, Massachusetts, USA). The integrated peak intensities of hyperpolarized [1‐13C]
pyruvate and [1‐13C]lactate were fitted to a simple product model,20 where kP is a first‐order rate constant describing the labeling of lactate (L) from
pyruvate (P) and R1,L describes the loss of polarization in lactate as a result of spin–lattice relaxation (R1,L):
dL
dt
¼ kPP− R1;L þ R1;Gd
 
L (1)
To account for the effect of Prohance, a second relaxation term (R1,Gd) was included in the model at time points after Prohance injection
(30–40 s). To avoid any bias arising from this approach, in animals not receiving Prohance (n = 5), R1,Gd was incorporated into the model at 35 s
after pyruvate injection, which yielded a value for R1,Gd of 0.001 ± 0.001 s
–1.
In another set of animals (n = 2), axial 13C chemical shift images (CSIs) (TR = 30 ms; TE = 1.5 ms; field of view, 40 mm × 40 mm; data matrix, 24 ×
24 with center‐out phase encoding order; spectral width, 6 kHz; total acquisition time, 30 s; flip angle, 5°) were acquired from an 8‐mm‐thick slice,
which was selected from the 1H images. Images were acquired 15 s after injection of [1‐13C]pyruvate, using a volume coil in transmit/receive mode.
The data were multiplied by a cosine function and zero‐filled to 128 points in both spatial directions, line‐broadened to 20 Hz and zero‐filled to
1024 points in the spectral dimension before Fourier transformation, phase and baseline correction and peak integration.
2.4 | Tissue and blood collection and analysis
2.4.1 | 13C experiments
Perchloric acid extracts of blood and tumor tissue from EL4 tumor‐bearing (n = 7) and non‐tumor‐bearing (n = 6) mice were prepared from animals
that had been anesthetized for 30 min and then injected with [3‐13C]pyruvate. Thirty minutes corresponds to the duration of the studies with
hyperpolarized [1‐13C]pyruvate. Thirty seconds after injection of [3‐13C]pyruvate (10 mL/kg, 82mM), blood was obtained by cardiac puncture and
the mice were sacrificed by cervical dislocation, followed by rapid excision and freeze‐clamping of tumors in liquid nitrogen‐cooled tongs. Blood
was collected into sodium fluoride‐coated tubes (BD Microtainer, Oxford, UK) and centrifuged (18 800 g) at 4°C for 2 min. Plasma was then added
to another Eppendorf tube with 600 μL of 7% perchloric acid (1: 8, w/v). In another cohort of mice (n = 3, tumor‐bearing; n = 4, non‐tumor bearing),
blood was withdrawn by cardiac puncture and 0.4 mL was added to a tube preheated to 37°C to which [3‐13C]pyruvate (40 μL, 82mM) was then
added rapidly and the tube was gently mixed. After 30 s, the blood samples were processed as above. In another set of animals (n = 5), anesthetized
by intraperitoneal injection of Hypnorm/Hypnovel, [1‐13C]lactate (45mM)21 was injected intravenously into tumor‐bearing animals that had received
either saline (n = 3) or 4‐CIN (n = 2) injections 5 min prior to lactate injection. Animals were killed 30 s later and the tumors were processed as above.
Perchloric acid extracts were prepared using ice‐cold 7% perchloric acid (1: 8, w/v), which were then neutralized with KOH, lyophilized and
dissolved in 99.9% deuterium oxide. The experiments in which [3‐13C]pyruvate was added to samples of blood ex vivo showed that, following this
perchloric acid extraction procedure, ~90% of the added 13C label was recovered in pyruvate and lactate.
High‐resolution 1H and 1H‐decoupled 13C NMR spectra of plasma and tumor were obtained at 14.1 T (25°C, pH 7.2) using a 600‐MHz NMR
spectrometer (Bruker, Ettlingen, Germany) and a 5‐mm probe. The acquisition conditions were as follows: 1H, 90° pulses; spectral width, 7.3 kHz;
acquisition time, 4.5 s; 32 k data points; 64 transients; recycling time, 12.5 s; 13C, 30° pulses; spectral width, 36.0 kHz; acquisition time, 0.9 s; 32 k
data points; 2048 transients; recycling time, 14 s. Chemical shifts were referenced to 3‐(trimethylsilyl)‐2,2′,3,3′‐tetradeuteropropionic acid (TSP,
0.0 ppm). Spectral deconvolution and multiplet structures were analyzed using the PC‐based (Intel Centrino Platform) NMR program,
4 of 10 SERRAO ET AL.ACDSpecManager (ACD/Labs, Bracknell, Berkshire, UK). Data were zero‐filled twice and multiplied by an exponential function prior to Fourier
transformation. All NMR resonance areas were normalized to the integral of the 5mM TSP resonance.
2.4.2 | 14C experiments
[1‐14C]Pyruvate, with a specific activity of 50–60 mCi/mmol, was supplied by American Radiolabeled Chemicals (Royston, Hertfordshire, UK). An
82mM pyruvic acid solution containing 200 kBq 14C was injected per animal. The 14C pyruvic acid was mixed with cold pyruvic acid in order to
achieve the same pyruvate concentration as that used in the imaging experiments (10 mL/kg, 82mM).
Fifteen tumor‐bearing mice were maintained under anesthesia for 30 min (the duration of the hyperpolarized 13C studies) prior to injection
with [1‐14C]pyruvate. Animals were killed at 15, 30 and 60 s after injection and the blood and organs were removed. The organs were homogenized
in RIPA buffer (1: 5) (50mM HEPES, 1mM EDTA, 0.7% sodium deoxycholate, 1% Nonidet P‐40, 0.5 M lithium chloride, pH 7.6) using a Precellys 24
homogenizer (Stretton Scientific Ltd., Stretton, Derbyshire, UK) and the blood was centrifuged as described above. The counts from the tissues and
serum were determined using a liquid scintillation counter (Perkin Elmer, Beaconsfield, Buckinghamshire, UK). The measured radioactivity was nor-
malized to tissue weight or serum volume, accordingly.
2.5 | Statistical analysis
Data are reported as the mean ± standard error of the mean (SEM). Statistical significance was tested using Prism 6with a two‐tailedMann–Whitney
test, unpaired two‐tailed Student's t‐test or Kruskal–Wallis test when appropriate. p < 0.05 was considered to be significant.3 | RESULTS
3.1 | Biodistribution of pyruvate
The biodistribution of [1‐14C]pyruvate (10 mL/kg; 82mM; specific activity, 50–60 mCi/mmol) in EL4 tumor‐bearing mice was studied at 15, 30 and
60 s after intravenous injection (Figure 1). Only a small fraction of the injected [1‐14C]pyruvate was observed in the tumor, with a significant
increase occurring between 15 [1.16% injected dose (ID)/g tissue] and 60 s (1.98% ID/g). 14C levels in the plasma were ~15% ID/g and decreased
with time. As the blood volume in this tumor model is ~2% of the tumor volume, only ~15% of 14C label in the tumor will be in the blood pool. WeFIGURE 1 Biodistribution [percentage of injected dose (ID%)/g] of [1‐14C] pyruvate injected intravenously (10 mL/kg; 82mM; specific activity,
50–60 mCi/mmol). EL4 tumor‐bearing mice were injected at the indicated times and the tissues were harvested and weighed, and the
radioactivity was counted in a scintillation counter. The total amounts of radioactivity recovered from the indicated tissues were 55.9, 57.9 and
56.1 ID%/g at 15, 30 and 60 s, respectively
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tern of labeling was observed in the heart, which may be dominated by blood present in the ventricles. The decrease in blood activity was accom-
panied by small increases in all the other organs analyzed, including the brain. The total amount of radioactivity recovered from all the tissues
analyzed was unchanged over 60 s (Figure 1).
A 13C CSI acquired using a volume receiver coil at ~15 s after intravenous injection of hyperpolarized [1‐13C]pyruvate (10 mL/kg of 82mM) into
a tumor‐bearing mouse showed that the pyruvate signal was predominantly in the aorta and that the signals from [1‐13C]lactate were distributed
throughout the body. There was very little lactate signal in the aorta at this time point and only a small amount of pyruvate signal in the tumor
(Figure 2). The pyruvate peak integral in the spectrum from the aorta was 14 times greater than the pyruvate peak integral in the spectrum from
the tumor. Given a tumor blood volume of ~2%, the blood pyruvate signal will contribute ~30% of the total tumor pyruvate signal (see broken line
in Figure 2B).3.2 | Concentrations of 13C‐labeled pyruvate and lactate in tumor and blood
The concentrations of 13C‐ and 12C‐labeled pyruvate and lactate were measured in blood and tumor tissue at 30 s after injection of [3‐13C]pyruvate
(10 mL/kg, 82mM) (Table 1). The [3‐13C]pyruvate concentration in the tumor was undetectable, with all the observable label present in [3‐13C]lac-
tate (0.78 μmol/g). Correcting for the presence of natural abundance 13C (1.1%) present in the lactate pool (0.19 μmol/g), this represents 4% of ID/
g of 13C‐labeled pyruvate (16.4 μmol). This shows that, as soon as the labeled pyruvate enters the cell, the 13C label is rapidly diluted into the
endogenous lactate pool in the exchange catalyzed by LDH.17,23 The total tumor lactate concentration did not change significantly following the
injection of pyruvate (Table 1), consistent with the observed isotope labeling being a result of the exchange of label rather than net conver-
sion.11,24,25 The low value for %ID/g is consistent to some extent with the [1‐14C]pyruvate biodistribution data, which showed that, at 30 s, only
~1% of the ID was in the tumor. The 14C data represent label in both pyruvate and lactate. The sum of the 13C‐labeled pyruvate and lactate con-
centrations in the blood was 3.6 μmol/g (Table 1). Correcting for natural abundance 13C in lactate and pyruvate (0.2 μmol/g), this represents
approximately 21% of the ID. Again, this is comparable with the [1‐14C]pyruvate biodistribution data (Figure 1), which showed that, at 30 s, there
was approximately 15% of the injected 14C label in the blood. The lactate concentration was three times higher in the blood of tumor‐bearing mice
(15 ± 3 μmol/g) when compared with controls (5.3 ± 2.1 μmol/g). The presence of a tumor has been shown previously to lead to an increase in
blood lactate concentration.26 The blood [3‐13C]pyruvate and [3‐13C]lactate concentrations were 1.2 and 2.4 μmol/g, respectively, in tumor‐bear-
ing mice, and 3.3 and 1.8 μmol/g, respectively, in non‐tumor‐bearing animals. These results show that there was significant labeling of blood lactate
and that this increased at higher lactate concentrations. The increased labeling at high lactate concentrations is consistent with previous studies
showing that increased lactate concentrations increase the rate of LDH‐catalyzed exchange of 13C label between pyruvate and lactate.10,11,24,27FIGURE 2 Images of pyruvate and lactate acquired 15 s after injection of hyperpolarized [1‐13C]pyruvate in a tumor‐bearing mouse (A). The
grayscale image is an anatomical 1H image of tissue water. The blood vessel (yellow), tumor (red) and bowel (blue) regions are outlined. The
false‐color images show the intensities of the pyruvate (172.9 ppm) and lactate (185.1 ppm) signals normalized to the maximum pyruvate signal in
the slice. A lactate image from the same slice, multiplied by a factor of five, is also shown. Summed spectra from the blood vessel, bowel and tumor
regions are shown below the corresponding images (B). The y‐scale for the bowel and tumor spectra has been multiplied by a factor of five to aid
visualization. The broken line in the tumor spectrum shows the blood vessel spectrum, which has been scaled to take account of the fact that the
blood volume is ~2% of the tumor volume
TABLE 1 Total and 13C‐labeled pyruvate and lactate concentrations in blood and tumor
Mouse Tissue
Total pyruvate
concentration
(μmol/g)
Total lactate
concentration
(μmol/g)
13C‐labeled
pyruvate
(% of total)
13C‐labeled
lactate
(% of total)
Tumor‐bearing Blood (n = 7) 3.0 ± 1.2 15 ± 3 **(a) 40 ± 11**(a) 16 ± 3**(a)
Tumor (n = 7) n.q. 17 ± 3 – 4.6 ± 1.6
Tumor with no [3‐13C]pyruvate injection (n = 3) n.q 14 ± 4 – –
Non‐tumor‐bearing Blood (n = 6) 4.6 ± 2.4 5.3 ± 2.1 72 ± 11 33 ± 7
Mice were injected with 10 mL/kg of an 82mM solution of [3‐13C]pyruvate, except where indicated. Blood was obtained at 30 s by cardiac puncture and the
tumors were immediately freeze‐clamped and extracted for 13C nuclear magnetic resonance (NMR) analysis of 13C labeling. Tumor samples from animals not
injected with [3‐13C]pyruvate were taken and the blood was used to measure exchange in the blood pool (Table 2). n.q., not quantifiable; n, number of
animals.
aSignificantly different compared with levels in the blood of non‐tumor‐bearing mice; mean ± standard deviation (SD); p < 0.01.
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make only an ~10% contribution to the concentrations measured in the tumor (0.78 μmol/g). This is consistent with our failure to detect any 13C‐
labeled pyruvate in the tumor (Table 1). To determine the relative contributions of blood cells and other tissues to the lactate labeling observed in
the blood pool, we added 3.28 μmol of [3‐13C]pyruvate to 0.44 mL of freshly drawn blood obtained by cardiac puncture and measured labeling in
pyruvate and lactate after incubation at 37°C for 30 s (Table 2). In blood from tumor‐bearing and non‐tumor‐bearing animals, 10% (1.2 μmol/g) and
9% (0.6 μmol/g), respectively, of the lactate became labeled (Table 2). Therefore, isotope exchange catalyzed by blood can account for approxi-
mately one‐half of the 13C‐labeled lactate observed in the blood pool at 30 s after injection of labeled pyruvate, the remainder presumably coming
from 13C label exchange in other tissues.
3.3 | Compartmentalization of hyperpolarized [1‐13C]lactate
Sequential injections of hyperpolarized [1‐13C]pyruvate (10 mL/kg, 82mM) (n = 4), followed ~35 s later by a gadolinium chelate (~0.75 mmol/kg
Prohance), were used to investigate the distribution of labeled lactate between intra‐ and extracellular pools in the tumors.18,19,28 Previous reports
have indicated that the rate of lactate transport to the extracellular compartment is only slightly slower than the rate of labeled lactate formation,19
and we have shown previously in EL4 tumor cells that transport and LDH activity have similar flux control coefficients for the exchange of
hyperpolarized 13C label.24 Injection of the gadolinium chelate resulted in an increased rate of decay of the lactate signal, which could not be explained
simply by the accelerated loss of pyruvate polarization (Figure 3). The broken lines in Figure 3 show the lactate signal that would have been observed
based on the observed pyruvate signal and assuming that kP does not change following the injection of the gadolinium chelate. This is consistent with
some fraction of the lactate signal coming from the extracellular compartment, whichwill be predominantly the interstitial space, given the low blood
volume. The administration of an MCT inhibitor (4‐CIN; 150 mg/kg, 0.2 mL intravenously), 3 min (n = 2) or 30 min (n = 4) prior to the injection of
hyperpolarized [1‐13C]pyruvate (10 mL/kg, 82mM) (n = 6), led to a 30% decrease (p < 0.05) in the apparent first‐order rate constant (kP) describing
the flux of hyperpolarized 13C label between the injected pyruvate and endogenous lactate pool (Table 3), consistent with 4‐CIN inhibition of pyru-
vate uptake.17,29 This inhibitor, which inhibits predominantly MCT1, also inhibits lactate transport, which was confirmed by the injection of 4‐CIN
5 min prior to the injection of thermally polarized [1‐13C]lactate (10 mL/kg, 45mM) and measurement of labeled lactate concentrations in tumor
extracts prepared 30 s later. There was an 85% decrease in the concentration of 13C‐labeled lactate measured in tumors treated with 4‐CIN (0.3 ±
0.1mM, p < 0.05, n = 2) when compared with controls treated with saline (2 ± 0.5mM, n = 3). There were no changes in the total tumor lactate con-
centration (12 ± 1mM). We have shown previously that EL4 tumors express both MCT1 andMCT4.24 The inhibition of lactate transport with 4‐CIN
decreased the apparent rate of decay of polarization in [1‐13C]lactate from 0.056 ± 0.004 to 0.041 ± 0.003 s–1 (p < 0.05) (Table 3).4 | DISCUSSION
The exchange of hyperpolarized 13C label between injected [1‐13C]pyruvate and the endogenous lactate pool is usually characterized by an appar-
ent first‐order rate constant,11,17,30 or by the ratio of the area under the lactate and pyruvate labeling curves, which is directly related to this rateTABLE 2 Exchange of 13C label between [3‐13C]pyruvate and endogenous lactate in blood
Source of blood
Total pyruvate
concentration
(μmol/g)
Total lactate
concentration
(μmol/g)
13C‐labeled
pyruvate (% of
total)
13C‐labeled
lactate (% of
total)
Tumor‐bearing mice (n = 3) 7 ± 3 12 ± 3 88 ± 2 10 ± 2
Non‐tumor‐bearing mice (n = 4) 7.8 ± 2.2 7 ± 3 92 ± 7 9 ± 2
[3‐13C]Pyruvate (3.28 μmol) was added to 0.44 mL of freshly withdrawn blood and incubated at 37°C for 30 s. The tissue was then extracted in perchloric
acid and 13C labeling was analyzed by 13C nuclear magnetic resonance (NMR) measurements on neutralized extracts.
FIGURE 3 Effect of injection of a gadolinium chelate (Prohance) on the tumor lactate signal intensity. The contrast agent was injected ~35 s after
injection of hyperpolarized [1‐13C]pyruvate at t = 0. The full line shows a fit to Equation 1. The broken line shows the expected lactate signal
intensity if the gadolinium (Gd) chelate had not been injected. 4‐CIN, α‐cyano‐4‐hydroxycinnamate
TABLE 3 Analysis of exchange rate constants and lactate polarization decay rates in tumors of untreated mice and mice treated with a mono-
carboxylate transporter (MCT) inhibitor (4‐CIN, α‐cyano‐4‐hydroxycinnamate). The animals were injected with a gadolinium chelate 35 s after
injection of hyperpolarized [1‐13C]pyruvate
kP (s
–1) R1 (s
–1) R1,Gd (s
–1)
Control (n = 9) 0.153 ± 0.03 0.056 ± 0.004 0.091 ± 0.011b
4‐CIN (n = 6) 0.102 ± 0.014* 0.041 ± 0.003a 0.084 ± 0.005
The control group includes animals with (n = 4) and without (n = 5) gadolinium chelate injection. Lactate peak intensities were fitted to Equation 1.
aDifferent from control, p < 0.05 (Student's t‐test).
bThe reported value is calculated only for animals receiving Prohance (n = 4). For control animals not receiving Prohance (n = 5), R1,Gd was 0.001 ± 0.001 s
–1.
SERRAO ET AL. 7 of 10constant.15 The rate constant is an apparent rate constant as it is an empirical measure of a process that includes pyruvate delivery to the tissue,
uptake into the cell and subsequent LDH‐catalyzed exchange of the hyperpolarized 13C label with lactate. As the rate of exchange is spatially het-
erogeneous,11 and in the absence of any imaging measurements, this apparent measured rate constant is also a reflection of the average rate for
the whole tumor. However, it is not a measure of the metabolically relevant flux, measured for example in mM s–1, as a change in this apparent rate
constant may indicate a change in flux or a change in the concentration of pyruvate at the exchange site. In order to obtain a true isotope flux mea-
surement, we need to know the concentration of pyruvate at the exchange site, which measurements with hyperpolarized [1‐13C]pyruvate cannot
readily provide.8,23 The biodistribution studies presented here with [1‐14C]pyruvate show that, in tumor‐bearing animals, very little of the injected
pyruvate reaches the tumor site; at 15 s, only 1.16% of the ID reaches the tumor. Measurements of pyruvate delivery to the tumor could not be
performed with 13C‐labeled pyruvate as it was below the level of detection (Table 1). However, as measurements of 13C label in blood pyruvate and
lactate (22% ID/g) were comparable with measurements of 14C label in the blood pool (15% ID/g), this suggests that the measurements of [1‐14C]
pyruvate at the tumor site can provide a surrogate measure that can be used to approximate the concentration of 13C‐labeled pyruvate. Using the
14C data, we can calculate that, at 15 s following injection, 0.19 μmol/g of hyperpolarized [1‐13C]pyruvate would have reached the tumor site. With
the 13C MRS measurements in vivo, which gave an apparent rate constant for the exchange of hyperpolarized 13C label between injected [1‐13C]
pyruvate and lactate of 0.153 ± 0.03 s–1 (Table 3), this gives an isotope label flux of 0.030 μmol/s/g tumor. Measurements of [3‐13C]lactate con-
centration in extracts of tumors that were freeze‐clamped at 30 s after injection of thermally polarized [3‐13C]pyruvate (Table 1) can be used to
estimate the true 13C label flux, which gave a flux of 0.026 μmol/s/g tumor. Given the likely errors introduced by tissue extraction, this is in remark-
ably good agreement with the flux estimated from the 14C and hyperpolarized 13C measurements, and demonstrates the internal consistency of the
data. Potentially the same experiment could be performed clinically using a PET/MR machine with hyperpolarized [1‐13C]pyruvate31 and [1‐11C]
pyruvate.32 However, the challenge would be to acquire the PET data sufficiently rapidly to obtain an estimate of the tumor pyruvate concentration
8 of 10 SERRAO ET AL.during the time in which the MRmeasurements of hyperpolarized 13C label exchange were being made and before there was significant loss of 11C‐
labeled material from the tissue. The estimates of label flux also show reasonably good agreement with previous measurements of 13C label flux
between pyruvate and lactate in suspensions of EL4 cells in vitro.24 At 0.16mM [1‐13C]pyruvate, the label flux in EL4 tumor cell suspensions, esti-
mated from the data shown byWitney et al.,24 is 3.5 fmol/min/cell. Assuming a tumor cell density in vivo of 5 × 108 cells/mL,33 this corresponds to
an extrapolated label flux in the tumor of 0.029 μmol/s/g tumor.
Previous diffusion measurements on EL4 tumors have shown that the labeled lactate observed following the injection of hyperpolarized [1‐
13C]pyruvate has a lower diffusion coefficient than pyruvate, suggesting that the labeled lactate is predominantly intracellular.17 However, the
reported diffusion coefficients in this previous study for pyruvate were slightly lower and for lactate slightly higher than those measured previously
using 1H diffusion spectroscopy for purely vascular or intracellular metabolites, respectively,34-36 suggesting that the observed lactate was present
in both the interstitial and intracellular spaces. That the tumor can release significant amounts of labeled lactate was confirmed here by the injection
of a gadolinium chelate, Prohance, 35 s following the injection of hyperpolarized [1‐13C]pyruvate (Figure 3). The increased rate of decay of the lac-
tate signal, which could not be explained by the accelerated decay of the [1‐13C]pyruvate polarization, demonstrated that lactate labeled intracel-
lularly had been released into the extracellular space. The export of hyperpolarized 13C‐labeled lactate has been observed previously in studies on
tumor cells in vitro.25,37,38 Further evidence for the release of labeled lactate in the tumor came from the effects of the inhibition of MCT activity
with 4‐CIN. This resulted in a significant, although relatively small (~30%), decrease in the apparent rate of polarization decay in [1‐13C]lactate (R1)
(Table 3), which will include contributions from spin–lattice relaxation and the export of lactate from the tumor. Assuming that MCT inhibition does
not affect the spin–lattice relaxation, this again suggests that there was significant loss of labeled lactate from the tumor cell, which was inhibited
by 4‐CIN. This modest decrease in [1‐13C]lactate R1, however, will have little effect on estimates of kP. We have shown previously that varying R1
for both [1‐13C]pyruvate and [1‐13C]lactate between 0.04 and 0.05 s–1 has only a small effect on the fitted value for kP (see supplementary figure 2
in Day et al.11). The relatively rapid release of lactate from the tumor cells is interesting in view of the growing evidence for a symbiotic relationship
between aerobic and hypoxic cancer cells within the same tumor, with lactate shuttling between these two cell populations.39 There has also been
a recent suggestion that cancer cells with high glycolytic activity have a capacity to evade immunosurveillance by diminishing T‐cell anti‐tumor
responses.40,41
The inhibition of MCT activity by 4‐CIN was demonstrated by showing inhibition of lactate labeling following injection of hyperpolarized [1‐
13C]pyruvate (Table 3) and also by showing the inhibition of tumor uptake of thermally polarized [1‐13C]lactate (10 mL/kg, 45mM). Interestingly,
the latter experiments showed that much more of the labeled lactate than labeled pyruvate reached the tumor. Although there was no detectable
13C‐labeled pyruvate and only 0.78 μmol/g of 13C‐labeled lactate in the tumors of animals injected with 10 mL/kg of 82mM 13C‐labeled pyruvate
(Table 1), which represents 4% of the injected pyruvate dose, there was ~2 μmol/g of 13C‐labeled lactate in animals injected with 13C‐labeled lac-
tate. Correcting for natural abundance 13C in the lactate present in the tumor prior to the injection of labeled lactate, this corresponds to ~21% of
the ID/g. This could be advantageous for experiments that use hyperpolarized 13C‐labeled lactate to measure LDH‐catalyzed exchange in tissues.42
Approximately 50% of the relatively high level of lactate labeling (2.4 μmol/g) observed in the blood of tumor‐bearing animals at 30 s following
[3‐13C]pyruvate injection (67% ID/g) (Table 1) could be explained by erythrocyte‐catalyzed exchange, as incubation of [3‐13C]pyruvate in freshly
drawn blood at 37°C for 30 s resulted in 1.2 μmol/g of labeled lactate (Table 2). The remainder of the labeled blood lactate presumably arose from
lactate that underwent exchange in other tissues and was then released into the blood pool. The labeled lactate concentration at 30 s was approx-
imately twice the concentration of 13C‐labeled pyruvate at this time point (1.2 μmol/g) (Table 1). CSIs acquired here, 15 s earlier (Figure 2), and a
time course of single‐shot three‐dimensional images acquired previously at 2‐s intervals up to 60 s after hyperpolarized [1‐13C]pyruvate injection,14
showed that the majority of observable pyruvate was in blood; the intense signal in the aorta in Figure 2 should be noted, whereas labeled lactate
was largely absent from the aorta and was more homogeneously distributed throughout the body, with a large fraction in the tumor. The implica-
tions of these observations are that labeled lactate released into the circulation at early time points is too low in concentration to be detected and
at later time points has lost a substantial amount of polarization.5 | CONCLUSIONS
We have shown that only a small fraction of injected 13C‐labeled pyruvate reaches the tumor and the pyruvate that enters the cell rapidly
exchanges its 13C label with lactate in the reaction catalyzed by LDH, the label becoming substantially diluted in the large endogenous lactate pool.
Estimation of the pyruvate concentration in the tumor and multiplication of this concentration by the apparent first‐order rate constant (kP)
describing the exchange of hyperpolarized 13C label between injected [1‐13C]pyruvate and the endogenous lactate pool gave a label flux that
was in good agreement with that determined directly by measurement of the concentration of 13C label incorporated into lactate in tumor extracts.
This suggests that simultaneous PET/MR studies in the clinic with hyperpolarized [1‐13C]pyruvate and [1‐11C]pyruvate could be used to estimate
metabolically relevant isotope fluxes from the 13C data. There was measurable export of hyperpolarized 13C‐labeled lactate into the tumor extra-
cellular space and the release of 13C‐labeled lactate from the tumor and from other tissues can explain the relatively high level of labeled lactate in
the blood of animals injected with 13C‐labeled pyruvate. This labeled lactate was not detected in images acquired from animals injected with
hyperpolarized [1‐13C]pyruvate, presumably because, at earlier time points, there was little labeled lactate in the blood and, at later time points,
there will have been substantial loss of polarization.
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